Mouse IL-23 alpha&IL-12 beta Heterodimer Protein, His Tag&Tag Free
分子別名（Synonym）
IL-23 alpha & IL-12 beta
表達區(qū)間及表達系統(tǒng)（Source）
Mouse IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free (ILB-M52W7) is expressed from human 293 cells (HEK293). It contains AA Val 22 - Ala 196 (IL23A) & Met 23 - Ser 335 (IL12B) (Accession # Q9EQ14-1 (IL23A) & P43432-1 (IL12B)).
Predicted N-terminus: His (IL23A) & Met 23 (IL12B)
蛋白結(jié)構(gòu)（Molecular Characterization）
Mouse IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free, produced by co-expression of IL-23A and IL-12B, has a calculated MW of 20.5 kDa (IL-23A) and 35.8 kDa (IL-12B). Subunit IL-23A is fused with a polyhistidine tag at the N-terminus and subunit IL-12B contains no tag. The reducing (R) protein migrates as 20 kDa (IL-23A) and 45 kDa (IL-12B) respectively due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
白細胞介素-23亞基α（IL-23α）可以與IL12B結(jié)合形成IL-23白細胞介蛋白，這是一種異二聚體細胞因子，在先天免疫和適應(yīng)性免疫中起作用。IL-23可能與IL-17共同構(gòu)成外周組織對感染的急性反應(yīng)。IL-23與由IL12RB1和IL23R組成的異二聚體受體復(fù)合物結(jié)合，激活Jak-Stat信號級聯(lián)，刺激記憶而不是幼稚T細胞，并促進促炎細胞因子的產(chǎn)生。IL-23誘導(dǎo)自身免疫性炎癥，因此可能是自身免疫性炎性疾病的原因，可能對腫瘤發(fā)生很重要。
關(guān)鍵字： IL23A蛋白;IL12B蛋白;IL23A & IL12B;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。